Screener
Aclaris Therapeutics ACRS Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
FAQ
- What is Aclaris Therapeutics's operating lease liabilities (current)?
- Aclaris Therapeutics (ACRS) reported operating lease liabilities (current) of $588K in Q2 2026.
- How has Aclaris Therapeutics's operating lease liabilities (current) changed year-over-year?
- Aclaris Therapeutics's operating lease liabilities (current) increased by 14.2% year-over-year, from $515K to $588K.
- What is the long-term trend for Aclaris Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's operating lease liabilities (current) has grown at a -1.8% compound annual growth rate (CAGR), from $603K to $551K.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Aclaris Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude